International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 006-014
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
THE EFFICACY AND TOLERABILITY OF INTERMEDIATE HIGH DOSE INTERFERON ALPHA 2B TREATMENT AS AN ADJUVANT THERAPY OF HIGH RISK MALIGNANT MELANOMA
Bülent KARABULUT1, V. Canfeza SEZGİN1, Gamze GÖKSEL2, Ulus A. ŞANLI1, Rüçhan USLU1, Erdem GÖKER1
1Ege Üniversitesi Tıp Fakültesi Tülay Aktaş Onkoloji Hastanesi Medikal Onkoloji Bilim Dalı, İZMİR
2Celal Bayar Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, MANİSA
Keywords: Malignant melanoma, Adjuvant therapy, Interferon alpha 2B
There are still ongoing clinical trials and debates about adjuvant treatment of malignant melanoma. Between 1995 and 2004, fourty-nine patients with high risk operated non-metastatic malignant melanoma who had been treated with intermediate dose of interferon alpha were enrolled to the study. Twenty-three patients had regional lymph node metastasis at the time of diagnosis. Patients were treated with interferon alpha 2b (10 million units/day, five times a week for four weeks) as an induction therapy, followed by interferon alpha 2b (10 million units/day interferon three times a week for eleven months) as a maintanence therapy. The median follow-up time was 35 months (range 2-101 months). In this period, 7 (14%) of patients had local recurrence, 12 (24%) of patients had regional lymph node metastasis and 20 (41%) of patients had distant metastasis. The 5-years overall survival, disease free survival and distant metastasis free survival rate of patients were 68%, 32% and 54% respectively. Therapy was well tolerated, no grade 4 toxicity related to therapy was observed. Comparing to natural history of malignant melanoma, these results are found to be encouraged.
Bülent KARABULUT1, V. Canfeza SEZGİN1, Gamze GÖKSEL2, Ulus A. ŞANLI1, Rüçhan USLU1, Erdem GÖKER1
1Ege Üniversitesi Tıp Fakültesi Tülay Aktaş Onkoloji Hastanesi Medikal Onkoloji Bilim Dalı, İZMİR
2Celal Bayar Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, MANİSA
Keywords: Malignant melanoma, Adjuvant therapy, Interferon alpha 2B
There are still ongoing clinical trials and debates about adjuvant treatment of malignant melanoma. Between 1995 and 2004, fourty-nine patients with high risk operated non-metastatic malignant melanoma who had been treated with intermediate dose of interferon alpha were enrolled to the study. Twenty-three patients had regional lymph node metastasis at the time of diagnosis. Patients were treated with interferon alpha 2b (10 million units/day, five times a week for four weeks) as an induction therapy, followed by interferon alpha 2b (10 million units/day interferon three times a week for eleven months) as a maintanence therapy. The median follow-up time was 35 months (range 2-101 months). In this period, 7 (14%) of patients had local recurrence, 12 (24%) of patients had regional lymph node metastasis and 20 (41%) of patients had distant metastasis. The 5-years overall survival, disease free survival and distant metastasis free survival rate of patients were 68%, 32% and 54% respectively. Therapy was well tolerated, no grade 4 toxicity related to therapy was observed. Comparing to natural history of malignant melanoma, these results are found to be encouraged.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |